Dialysis Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Dialysis is a life-sustaining renal replacement therapy (RRT) that removes metabolic waste products, excess fluid, and toxins from the blood when the kidneys have lost their ability to perform this function. It is required when kidney function has declined to the point where the patient develops symptoms of uraemia — the clinical syndrome of end-stage renal disease (ESRD) — typically when the estimated glomerular filtration rate (eGFR) falls below 10–15 mL/min/1.73m². Globally, approximately 3.5 million people are on maintenance dialysis, a number projected to double by 2030.

There are two primary modalities of dialysis: haemodialysis (HD), in which blood is removed from the body, filtered through an artificial membrane in a dialysis machine, and returned — performed three times weekly, each session lasting 3–5 hours, either in a hospital or dialysis centre, or self-administered at home; and peritoneal dialysis (PD), in which dialysis fluid (dialysate) is instilled into the peritoneal cavity through a surgically placed catheter, using the patient's peritoneal membrane as the dialysis membrane. PD is performed daily, either manually as continuous ambulatory peritoneal dialysis (CAPD) with four to five exchanges per day, or automatically overnight using a PD cycler machine (automated PD, APD).

The clinical pathway for dialysis initiation begins with nephrology follow-up as CKD progresses: vascular access creation (arteriovenous fistula formation, ideally 6–12 months before anticipated dialysis start) or PD catheter placement is planned well in advance. Education about modality choice (HD vs PD vs home HD vs pre-emptive transplantation) is provided to patients and families, enabling informed decision-making. Emergency dialysis initiation — for acute kidney injury or uraemic emergency — uses a temporary vascular access catheter inserted into the jugular or femoral vein.

Dialysis is required for end-stage kidney disease (ESKD) from any cause where the kidneys can no longer sustain life. The most common causes requiring dialysis include diabetic nephropathy (the leading cause globally — approximately 40% of new dialysis patients), hypertensive nephrosclerosis, glomerulonephritis (IgA nephropathy, focal segmental glomerulosclerosis, lupus nephritis), polycystic kidney disease, and obstructive nephropathy.

Acute indications for emergency dialysis — regardless of chronic kidney status — include: severe hyperkalaemia (potassium above 6.5 mmol/L with ECG changes), severe metabolic acidosis (pH below 7.15–7.2) unresponsive to bicarbonate, fluid overload causing pulmonary oedema refractory to diuretics, symptomatic uraemia (pericarditis, encephalopathy, bleeding from platelet dysfunction), and certain poisonings or drug overdoses (e.g., lithium, methanol, ethylene glycol, salicylates) where the offending substance is dialysable. Dialysis is used as a bridge to kidney transplantation — the gold standard renal replacement therapy — while patients await a suitable organ.

Dialysis is recommended when eGFR falls below 10–15 mL/min/1.73m² with symptoms of uraemia, or below 5–6 mL/min/1.73m² regardless of symptoms. The choice between HD and PD depends on multiple factors: patient preference, social circumstances and home environment, residual kidney function (PD better preserves residual function), peritoneal membrane characteristics (PD unsuitable with previous extensive abdominal surgery or active peritoneal disease), vascular access suitability, and medical comorbidities (HD is preferred for patients who cannot perform or tolerate the catheter exchanges of PD; PD is preferred for patients with haemodynamic instability, needle phobia, or cardiovascular fragility).

Patients who are not candidates for dialysis include those with terminal illness where dialysis would not extend quality life (conservative kidney management — supportive care without dialysis — is a valid and evidence-based alternative for elderly patients with multiple comorbidities). In elderly patients with multiple comorbidities, conservative management may result in similar survival to dialysis while offering better quality of life by avoiding the burdens of three-weekly clinic attendance.

Haemodialysis options range from conventional in-centre HD (three 4-hour sessions per week at a dialysis centre) to home HD in multiple formats: conventional home HD (standard three weekly sessions self-performed at home with partner assistance), short daily home HD (five to seven 2–3 hour sessions per week), and nocturnal home HD (three to seven long 8-hour sessions per week during sleep). Increased HD frequency and duration improves phosphate control, blood pressure, and quality of life compared to conventional three-weekly HD.

Vascular access for HD — essential for repeated blood access — is created in advance: an arteriovenous fistula (AVF) is the gold standard access, created surgically by anastomosing a forearm or upper arm artery to a vein, which over 6–12 weeks matures into a robust, high-flow vessel suitable for repeated needle cannulation. AVF patency at 1 year is 60–80% and at 5 years is 50–70%. Arteriovenous grafts (synthetic PTFE conduits) are used when suitable native veins are unavailable. Tunnelled cuffed central venous catheters are placed for immediate HD access but carry higher infection and thrombosis risks than AVF/AVG.

Peritoneal dialysis offers CAPD (four to five manual 2-litre bag exchanges per day, each taking 20–30 minutes, performed by the patient or carer) and APD/CCPD (automated cycler performs 8–12 exchanges overnight while the patient sleeps, with or without a daytime 'dwell'). PD provides continuous dialysis 24 hours/day, maintaining more stable fluid and electrolyte levels than intermittent HD.

Dialysis is life-sustaining — without it, ESKD is fatal within days to weeks. Maintenance dialysis enables patients with ESKD to survive for years to decades, with substantial quality of life. Median survival on dialysis in high-income countries is 3–5 years; patients under 40 have median survival of 10–15 years on dialysis. Younger patients with diabetic ESKD have 5-year survival rates of 30–40% on dialysis, compared to 70–80% with kidney transplantation — illustrating the superiority of transplantation where possible.

PD is associated with better preservation of residual kidney function over the first 2–3 years compared to HD, which translates to better phosphate control, better fluid balance, and possibly better survival. Home HD (nocturnal or short daily) is associated with improved blood pressure, better left ventricular regression, lower erythropoietin requirements, improved phosphate control, and better quality of life compared to conventional in-centre HD in multiple observational studies and small RCTs.

Haemodialysis complications include intradialytic hypotension (25–30% of sessions) — caused by rapid fluid removal — which is managed by slowing the ultrafiltration rate, reducing dialysate temperature, and haemodynamic profiling. Vascular access complications are a major source of morbidity: AVF thrombosis (20% per year), AV graft infections (10–15% per year), and central catheter-related bacteraemia (1–3 per 1000 catheter-days) cause significant hospitalisation. Dialysis-related amyloidosis — deposition of beta-2 microglobulin in joints and bones — affects long-term HD patients (typically after 10+ years) causing carpal tunnel syndrome, arthropathy, and destructive spondyloarthropathy.

Peritoneal dialysis complications include peritonitis — infection of the peritoneal cavity via the catheter — occurring approximately once every 24–36 patient-months in experienced centres. Peritonitis is the leading cause of PD technique failure (conversion to HD) and carries a mortality rate of 1–6% per episode. Catheter exit site and tunnel infections, PD catheter malfunction (poor flow, dislocation), abdominal wall complications (hernia, leak), and progressive peritoneal membrane failure (loss of dialysis efficacy over years due to membrane injury) are other PD-specific complications.

Maintenance dialysis patients require intensive ongoing medical follow-up. Monthly blood monitoring includes urea, creatinine, electrolytes, calcium, phosphate, parathyroid hormone (quarterly), bicarbonate, full blood count, haematinics, and dialysis adequacy measures (Kt/V for HD; weekly creatinine clearance for PD). Blood pressure is reviewed at every HD session. Medication review includes erythropoiesis-stimulating agents (ESA) for renal anaemia, IV iron, vitamin D analogues, and phosphate binders — a typical ESKD patient takes 10–15 medications.

Annual review covers: echocardiography (left ventricular hypertrophy and systolic function are powerful cardiovascular predictors in dialysis), access patency review, assessment for transplant listing (if not already listed), nutritional status (serum albumin, BMI, dietary assessment), and quality of life measures. Transplant workup — cross-matching, tissue typing, comorbidity assessment for surgical fitness — is initiated when appropriate so that pre-emptive transplantation or early post-listing transplantation is achievable.

Dialysis is one of the most expensive healthcare treatments globally. In the United States, annual in-centre HD costs $90,000–$100,000 per patient. PD costs $60,000–$75,000 annually. Home HD costs vary depending on modality and training costs. Medicare in the US covers ESKD dialysis costs for most patients through the ESRD programme, but out-of-pocket costs (copayments, medications, transport) remain substantial.

For medical tourists and international patients without government-funded dialysis coverage, costs in medical tourism destinations are dramatically lower. In India, in-centre HD costs $25–$60 per session (approximately $3,600–$8,600 annually for three-weekly dialysis) — 80–90% savings versus US rates. Thailand: $40–$100 per session. Turkey: $30–$80 per session. PD supplies (dialysate bags, cycler consumables) cost $500–$1,500 per month in India versus $3,000–$5,000 per month in the US. JCI-accredited dialysis centres in these countries offer modern dialysis equipment (Fresenius, Baxter, Gambro machines), biocompatible membranes, and nephrologist oversight at a fraction of Western costs, making long-stay dialysis programmes highly attractive to international patients.

Kidney transplantation is the superior alternative to dialysis for eligible patients with ESKD — it provides better survival, quality of life, and long-term metabolic outcomes compared to any form of dialysis, at lower long-term cost. Living donor kidney transplantation is preferred over deceased donor due to better graft survival and shorter waiting time. Pre-emptive transplantation — performed before dialysis is required — achieves the best outcomes of all. All dialysis patients should be assessed for transplant eligibility and listed early.

Conservative kidney management (CKM) — also called supportive care or palliative kidney management — is an evidence-based alternative to dialysis for elderly patients with multiple comorbidities, cognitive impairment, or limited functional status where the burdens of dialysis outweigh the benefits. CKM focuses on symptom management (uraemic pruritus, restless legs, pain, breathlessness, nausea), dietary measures to slow uraemia progression, and advance care planning. Median survival with CKM versus dialysis in elderly patients with multiple comorbidities is comparable in some studies, with better patient-reported quality of life on CKM.